Literature DB >> 30115213

An intensive personalised support approach to treating individuals with psychosis and co-morbid mild intellectual disability.

M Raftery1, K Burke2, N Murray3, O O'Duinn1, I Murray1, B Hallahan1.   

Abstract

OBJECTIVES: To evaluate the clinical benefits and associated cost effectiveness of an intensive personalised support (IPS) approach for clients suffering from psychosis and co-morbid mild intellectual disability (ID).
METHOD: Four individuals with a psychotic disorder and co-morbid mild ID participated in an 18-month IPS rehabilitative intervention. Biopsychosocial measures were used to evaluate clinical effectiveness. A cost analysis was undertaken to examine the cost effectiveness of the intervention.
RESULTS: Reductions in psychopathology including anxiety symptoms were noted in all individuals. In addition, increased functioning and quality of life were demonstrated in all cases. Overall cost reductions were noted in inpatient care, accommodation and legal/emergency expenses.
CONCLUSION: The IPS approach was clinically effective particularly in addressing individual's psychosocial needs, psychological functioning, daily living skills and overall quality of life. Costs had decreased for three of the four individuals, ranging from a 17% to 46% savings. The findings highlight that the intervention was cost effective in most cases at this early stage. However, further research is necessary in order to ascertain if cost savings occur over time.

Entities:  

Keywords:  Co-morbid; intensive personalised support; mild intellectual disability; psychosis

Year:  2017        PMID: 30115213     DOI: 10.1017/ipm.2016.19

Source DB:  PubMed          Journal:  Ir J Psychol Med        ISSN: 0790-9667


  1 in total

Review 1.  Psychosocial interventions for older people with intellectual disabilities and the role of support staff: A systematic review.

Authors:  Marloes Thalen; Karin M Volkers; Wietske M W J van Oorsouw; Petri J C M Embregts
Journal:  J Appl Res Intellect Disabil       Date:  2021-11-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.